{"article_id": "COO_q4_2021.txt", "article": ["regarding fourth quarter results and reporting all percentages on a constant currency basis , consolidated revenues were $ 759 million , with coopervision at $ 565 million , up 11 % ; and coopersurgical at $ 194 million , up 11 % .", "non-gaap earnings per share were $ 3.28 .", "for coopervision , our daily silicone hydrogel portfolio led the way , growing 19 % .", "for the regions , the americas grew 6 % , led by our daily silicone hydrogel lenses , with particular strength in myday , where we continue seeing strong fit activity .", "emea grew a healthy 15 % , with improving consumer activity and strength in our key accounts driving growth and share gains .", "asia pac grew 14 % , led by a steady improvement in consumer activity and success with several new product launches .", "our portfolio grew 63 % to $ 21 million , with misight up 165 % to $ 7 million and ortho k products up 40 % .", "we reached our goal of $ 65 million for the year , up 76 % year over year , and our momentum is strong .", "regarding misight , we did n't quite reach our target this quarter , but we did reach $ 19 million in sales for the full year , up a very impressive 149 % year over year .", "we 've also assembled an advisory board of key opinion leaders , whose affiliated hospitals represent over 50 % of myopia management contact lens volume in china .", "as a reminder , childhood myopia rates in china are estimated at over 80 % , and reducing myopia is a priority for the chinese government , so the opportunity is significant .", "it cuts myopia progression by roughly 59 % on average .", "overall , on myopia management , our momentum is strong , and we 're still targeting constant currency growth of over 50 % in fiscal 2022 , to roughly $ 100 million in sales .", "to conclude on vision , we estimate the overall contact lens market grew 7 % in calendar q3 , while coopervision grew 8 % even as new fits remain below pre-covid levels .", "data , roughly 64 % of eye care practitioners stated they had capacity to serve more patients but cannot , mostly due to staffing challenges .", "having said that , trends are positive , and we expect the market to grow in the 4 % to 6 % range this coming year , supported by improving fit activity in the u.s. and emea and reopening activity in asia pac .", "meanwhile , the long - term macro growth trends remain solid , with roughly one - third of the world being myopic today and that expected to increase to 50 % by 2050 .", "our fertility business performed exceptionally well , growing 24 % year over year to $ 82 million .", "regarding the broader fertility industry , our addressable market is approaching $ 2 billion , with 5 % to 10 % long - term growth expected .", "it 's estimated that one in eight couples has trouble getting pregnant due to a variety of factors , such as increasing maternal age , and that more than 100 million individuals worldwide suffer from infertility .", "within our office and surgical unit , we grew 3 % .", "medical devices performed well , growing 20 % , led by our portfolio of uterine manipulators , several of our surgical devices and our next - generation endosee advance product line .", "meanwhile , paragard declined 17 % , largely as forecasted due to buy - in activity from last quarter 's price increase .", "lastly , for coopersurgical , we recently announced an agreement to acquire generate life sciences for $ 1.6 billion .", "roughly one - third of the business is in fertility , which we estimate will grow 5 % to 10 % long - term , supported by general industry growth .", "two - thirds of the business is in cord blood and cord tissue storage , which we expect to grow 3 % to 5 % long term .", "consolidated , this business offers long - term sustainable growth of 4 % to 6 % , and we believe there are opportunities to push that range higher with potential revenue synergies as we leverage our expertise .", "fourth quarter consolidated revenues increased 11 % year over year and also 11 % in constant currency to $ 759 million .", "consolidated gross margin decreased year over year by 20 basis points to 67.5 % driven primarily by currency , partially offset by lower manufacturing costs at coopervision .", "operating expenses grew 16 % as strategic investments in sales and marketing to support myopia management and fertility continued .", "consolidated operating margins were 24.9 % , down from 26.8 % last year .", "interest expense was $ 5 million on lower average debt , and the effective tax rate was 10.3 % , helped by stock option exercises in the quarter .", "non-gaap earnings per share was $ 3.28 , with roughly 49.9 million average shares outstanding .", "fx negatively impacted us and was roughly $ 0.05 worse than expected when we gave guidance last quarter .", "free cash flow was solid at $ 110 million , comprised of $ 175 million of operating cash flow , offset by $ 65 million of capex .", "net debt decreased to $ 1.4 billion , and our adjusted leverage ratio improved to 1.38 times .", "moving to 2022 guidance and excluding the recently announced generate life sciences acquisition , consolidated revenues are expected to be in the range of $ 3.032 billion to $ 3.090 billion , up 6 % to 8 % in constant currency , with coopervision revenues between $ 2.225 billion and $ 2.267 billion , up 6 % to 8 % in constant currency , and coopersurgical revenues between $ 807 million and $ 823 million , up 6 % to 8 % in constant currency .", "non-gaap earnings per share is expected to range from $ 13.60 to $ 14 , up 9.5 % to 12.5 % in constant currency .", "and the tax rate is expected to be around 13 % .", "at the midpoint of guidance , this equates to constant currency revenue growth of roughly 7 % and constant currency earnings per share growth of roughly 11 % .", "regarding currency on a year - over - year basis , we 're expecting an fx headwind of roughly 2.5 % on revenues and 7 % on eps .", "this impact will be most detrimental in q1 , where we 're expecting earnings per share in the $ 3 to $ 3.10 range .", "as of today , we 're optimistic we 'll close in the next couple of weeks , which would give us roughly 10.5 months of their operations in our fiscal 2022 .", "as previously announced , generate has roughly $ 250 million in trailing 12 - month revenue .", "gross margins are expected to be roughly 70 % .", "as we are now closer to securing permanent financing for this transaction , we are updating our year one non-gaap earnings per share accretion estimate to around $ 0.50 and would add that we expect this accretion to improve in year two with synergies ."], "summary_gold": "q4 non -gaap earnings per share $ 3.28 .<q>q4 revenue rose 11 percent to $ 759.1 million .<q>initiating fiscal year 2022 guidance .<q>sees fiscal 2022 non -gaap diluted earnings per share $ 13.60 - $ 14.00 .<q>fiscal year 2022 guidance does not include generate life sciences acquisition .", "summary_pred": "non-gaap earnings per share was $ 3.28 , with roughly 49.9 million average shares outstanding .<q>consolidated operating margins were 24.9 % , down from 26.8 % last year .<q>interest expense was $ 5 million on lower average debt , and the effective tax rate was 10.3 % , helped by stock option exercises in the quarter .<q>to conclude on vision , we estimate the overall contact lens market grew 7 % in calendar q3 , while coopervision grew 8 % even as new fits remain below pre-covid levels .<q>fx negatively impacted us and was roughly $ 0.05 worse than expected when we gave guidance last quarter .<q>operating expenses grew 16 % as strategic investments in sales and marketing to support myopia management and fertility continued .<q>it 's estimated that one in eight couples has trouble getting pregnant due to a variety of factors , such as increasing maternal age , and that more than 100 million individuals worldwide suffer from infertility .<q>for coopervision , our daily silicone hydrogel portfolio led the way , growing 19 % .<q>emea grew a healthy 15 % , with improving consumer activity and strength in our key accounts driving growth and share gains .<q>within our office and surgical unit , we grew 3 % .<q>data , roughly 64 % of eye care practitioners stated they had capacity to serve more patients but cannot , mostly due to staffing challenges .<q>our portfolio grew 63 % to $ 21 million , with misight up 165 % to $ 7 million and ortho k products up 40 % .<q>regarding currency on a year - over - year basis , we 're expecting an fx headwind of roughly 2.5 % on revenues and 7 % on eps .<q>free cash flow was solid at $ 110 million , comprised of $ 175 million of operating cash flow , offset by $ 65 million of capex .<q>overall , on myopia management , our momentum is strong , and we 're still targeting constant currency growth of over 50 % in fiscal 2022 , to roughly $ 100 million in sales .<q>consolidated gross margin decreased year over year by 20 basis points to 67.5 % driven primarily by currency , partially offset by lower manufacturing costs at coopervision .", "len_article": 46, "len_summary_gold": 5, "len_summary_pred": 16, "len_sent_scores": 46}